Befotertinib Mesylate

甲磺酸贝福替尼

Report date: 2024/03/12 10:13:57
NME

Base Information

Drug NameBefotertinib Mesylate
Drug Alias NameBefotertinib赛美纳D-0316BPI-D0316
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR L858R inhibitorsEGFR 19del inhibitors
TargetsEGFR T790MEGFR L858REGFR 19del
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2023/05/29
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInventisbio Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBetta Pharmaceuticals Co LtdInventisbio Co Ltd
Inactive CompaniesBetta
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A